Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.5705
+0.2229 (64.13%)
At close: Mar 28, 2025, 4:00 PM
0.5898
+0.0193 (3.38%)
After-hours: Mar 28, 2025, 4:57 PM EDT
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 103 employees as of December 31, 2024. The number of employees decreased by 182 or -63.86% compared to the previous year.
Employees
103
Change (1Y)
-182
Growth (1Y)
-63.86%
Revenue / Employee
$301,757
Profits / Employee
-$1,945,660
Market Cap
206.23M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LXRX News
- 6 hours ago - Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal - Market Watch
- 7 hours ago - Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga
- 9 hours ago - Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 - GlobeNewsWire
- 21 days ago - Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire
- 21 days ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 23 days ago - Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - GlobeNewsWire
- 25 days ago - Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - GlobeNewsWire